What's a little interesting is that except for knowing the trial is moving to cohort 6 everything else we know that you listed is at least three or four months old. Imagine what could have occurred in that time with higher dosing.
Anyway, it's very encouraging to see the trial progress without incident.
The reason why restaging to stable disease followed by progression did not impress is conveniently summed up in this abstract from 2009:
"With a high percentage of new oncologic agents failing in phase III studies, the confidence one has in predicting later success in randomized studies when stable disease alone is observed is understandably low. Continued uncertainty of the value of stable disease is based on the lack of precision in defining this as a meaningful outcome. With the term stable disease encompassing a broad range from <20% enlargement to <30% reduction using standard response criteria response evaluation criteria in solid tumors, what one refers to as stable disease is open to diverse interpretation."
News 
Market Data 
Discover 
AI
